Skip to main content

Table 3 Summary of number and percentage of subjects with treatment-emergent adverse events

From: Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study)

  Pateclizumab ADA Placebo
(n = 86) (n = 85) (n = 43)
Any AE 50 (58%) 65 (76%) 31 (72%)
Any SAE 0 (0%) 5 (6%) 1 (2%)
Any AE Grade ≥3 6 (7%) 8 (9%) 3 (7%)
Any drug-related AE 20 (23%) 26 (31%) 10 (23%)
Any AE within 24 hr of dosing 7 (8%) 27 (32%) 6 (14%)
Any SAE within 24 hr of dosing 0 (0%) 0 (0%) 0 (0%)
Any drug-related AE within 24 hr of dosing 4 (5%) 12 (14%) 5 (12%)
Any infection AE 25 (29%) 32 (38%) 19 (44%)
Any infection SAE 0 (0%) 2 (2%) 0 (0%)
Any infection AE Grade 3 or higher 0 (0%) 1 (1%) 0 (0%)
Any AE leading to discontinuation of study drug 2 (2%) 6 (7%) 1 (2%)
Any death 0 (0%) 0 (0%) 0 (0%)
  1. ADA, adalimumab; AE, adverse event; SAE, serious adverse event.